{"name":"Kati Järvelä","slug":"kati-j-rvel","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Prolonged-release oxycodone/naloxone","genericName":"Prolonged-release oxycodone/naloxone","slug":"prolonged-release-oxycodone-naloxone","indication":"Moderate to severe chronic pain requiring around-the-clock opioid therapy","status":"marketed"}]}],"pipeline":[{"name":"Prolonged-release oxycodone/naloxone","genericName":"Prolonged-release oxycodone/naloxone","slug":"prolonged-release-oxycodone-naloxone","phase":"marketed","mechanism":"Oxycodone acts as a mu-opioid receptor agonist for pain relief, while naloxone is an opioid antagonist included to reduce abuse potential by blocking euphoric effects if the formulation is tampered with.","indications":["Moderate to severe chronic pain requiring around-the-clock opioid therapy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}